ABIVAX Société Anonyme (ABVX)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
ABIVAX Société Anonyme has not issued a press release in this window.
SEC filings
All filings →ABIVAX Société Anonyme has not filed an SEC document in this window.
Insider trades
All insider trades →ABIVAX Société Anonyme has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for ABIVAX Société Anonyme in this window.
People at ABIVAX Société Anonyme
All people →No officers or directors have been indexed for ABIVAX Société Anonyme.
Quarterly financials
Full financials →No quarterly financials have been ingested for ABIVAX Société Anonyme.